A Single Dose Study of Debio 1450 in Healthy Subjects

NCT ID: NCT02162199

Last Updated: 2014-10-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2014-10-31

Brief Summary

The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study.

This study looks at what the body does to the drug. It measures how the amount of drug in blood and urine changes over time.

From the screening visit through the follow-up visit may be up to 40 days. Volunteers go to the clinic in Baltimore for a screening visit. The study doctor chooses qualified volunteers to participate or serve as alternates. Alternates might not actually complete the study procedures.

The study doctor divides participants into groups of eight. Six receive Debio 1450 and 2 receive Placebo. The drug each participant receives is decided by chance - like flipping a coin.

Eligible volunteers check into the clinic for testing and those chosen to participate remain for a 5-day/ 4-night stay. The clinic serves standard meals, except when fasting is required. Participants must stay at the clinic for the length of the study.

This study is a "dose escalation" study. That means that if no safety concerns come up a new group starts. Each new group of eight participants receives more capsules.

The study product is contained in capsules. Each capsule contains either placebo or 40 mg Debio 1450. After fasting overnight, the first two participants in the group receive their capsules. One gets Debio 1450 and one gets Placebo. If these participants tolerate side effects for 24 hours, the remaining six participants receive their assigned capsules.

The plan is to increase the dose for the next group. The study doctor reviews the measurements collected from each group after three days. He may decide to repeat, increase, or lower the dose or even stop the study. The most any participant receives is 800 mg in 20 capsules.

Conditions

Bacterial Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Debio 1450

Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions

Group Type: EXPERIMENTAL

Debio 1450

Intervention Type: DRUG

Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Placebo

Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Interventions

Debio 1450

Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Intervention Type: DRUG

Placebo

Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Is a healthy adult

2. Has met protocol-specified criteria for qualification and use of contraception

3. Is willing and able to remain confined in the study unit for the entire duration of the treatment period and comply with restrictions related to food, drink and medications

4. Has voluntarily consented to participate and provided written informed consent prior to any protocol-specific procedures

Exclusion Criteria

1. Has screening laboratory values outside protocol-specified limits

2. Has history of a clinically significant allergic drug reaction

3. Has donated a volume of plasma or whole blood within a time frame not allowed per protocol

4. Has historical or current use not allowed per protocol of:

1. over-the-counter medications

2. certain foods; dietary, mineral or herbal supplements

3. licit or illicit drugs (including experimental drugs, caffeine, nicotine and alcohol)

5. Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

1. the safety or well-being of the participant or study staff

2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)

3. the analysis of results

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Debiopharm International SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Azra Hussaini, MD

Role: PRINCIPAL_INVESTIGATOR

Early Phase Clinical Unit - Baltimore, USA

Locations

Early Phase Clinical Unit

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

217596

Identifier Type: OTHER

Identifier Source: secondary_id

Debio 1450-102

Identifier Type: -

Identifier Source: org_study_id